Claros Technologies Moves Forward with European Expansion and Pharmaceutical Manufacturing

Claros Technologies Advances in European Market

Claros Technologies, a global leader in permanent PFAS destruction technology, has announced significant strides in its European expansion and entry into the pharmaceutical manufacturing sector. The company recently completed a successful commercial pilot of its ClarosTechUV™ system at Bachem AG's flagship manufacturing site in Bubendorf, Switzerland.

Bachem is a prominent player in the pharmaceutical industry, specializing in the production of active pharmaceutical ingredients (APIs) for peptide and oligonucleotide therapies. This includes semaglutide, a critical ingredient in GLP-1 therapies, which are widely used for weight management and treating type 2 diabetes. The pilot project has proven the efficacy of the ClarosTechUV™ system, meeting or exceeding performance benchmarks set by Bachem during two weeks of testing under real manufacturing conditions.

Michelle Bellanca, CEO and co-founder of Claros Technologies, emphasized the importance of this collaboration. She stated, "This partnership with Bachem marks a pivotal moment for Claros and a significant advance for the global pharmaceutical industry." As the demand for peptide-based products increases, especially those pertaining to GLP-1 therapies, so does the imperative to responsibly manage environmental impacts resulting from the presence of ultrashort-chain PFAS, such as trifluoroacetic acid (TFA), in industrial wastewater.

The regulatory landscape around PFAS is changing rapidly, with increasing scrutiny from authorities in both Europe and the United States. European regulators are exploring broader restrictions on PFAS substances, while the U.S. Environmental Protection Agency is considering adding TFA to its Unregulated Contaminant Monitoring Rule for national drinking water standards. Against this backdrop, Bachem is proactively addressing these challenges by implementing ClarosTechUV™ to effectively manage TFA from the source, underpinning a commitment to sustainable pharmaceutical manufacturing even as regulations evolve.

ClarosTechUV™ is designed to seamlessly integrate into existing wastewater treatment systems, enabling manufacturers to effectively destroy PFAS without requiring major modifications to their processes. Unlike conventional PFAS treatment technologies that often create additional waste streams requiring management and disposal, ClarosTechUV™ uses a patented, environmentally friendly photochemical UV process that permanently destroys PFAS, including ultrashort-chain variants like TFA, on-site.

The pilot program at Bachem not only reinforces the effectiveness of the ClarosTechUV™ system but also supports Bachem's broader initiative to minimize TFA levels in its industrial wastewater, thus promoting environmentally responsible manufacturing practices. According to Patrick Barth, the Group Communications Director at Bachem, "After treating our industrial wastewater with ClarosTechUV™, only very low residual concentrations of TFA were detected."

André Casagrande, Plant Director at Bachem's Bubendorf facility, articulated the synergy between innovation and environmental responsibility at their company. He noted, "For us, innovation and environmental responsibility go hand in hand. We not only want to help people through our products but also play a responsible role towards our environment."

Designed for the Future of Pharmaceutical Manufacturing

The ClarosTechUV™ system is specifically tailored for high-flow industrial operations, capable of being integrated within existing wastewater treatment frameworks. Its distinct functionality, which entails the permanent destruction of PFAS, allows for significant improvements to environmental management in pharmaceutical operations. Data from the Bachem pilot will guide future engineering and design decisions for scaled-up commercial systems.

About Bachem AG

Bachem AG is a leading innovator in the development and production of peptides and oligonucleotides, boasting over 50 years of expertise. The company serves pharmaceutical and biotechnology firms globally, offering a wide array of products and services and operating internationally with headquarters in Switzerland and facilities in Europe, the United States, and Asia. Bachem is publicly listed on the Swiss Stock Exchange (SIX BANB).

About Claros Technologies

Founded in 2018 in Minneapolis, Claros Technologies specializes in PFAS destruction solutions for industrial wastewater and groundwater concerns. The company operates predominately through ClarosTech™, which focuses on industrial-scale UV systems that permanently eliminate target PFAS species, and ClarosLabs™, which is accredited for PFAS detection and analysis. Claros strives to eradicate the permanence associated with PFAS, actively working towards their complete destruction.

For further information about Bachem, visit their website. For details on Claros Technologies, explore their resources online.